



Press release  
Gothenburg, Sweden  
September 7, 2020. 14:45 CET

## **CELLINK have been granted funding totalling €3,910,000 from the EU as a part of the Horizon 2020 program. CELLINK's portion of the grant is €270,000**

The REPAIR project aims to develop a new approach and clinically applicable method in cardiac contraction assistance. Current medical or surgical treatments cannot restore muscular contractility in heart failure and atrial fibrillation, two of the most common and serious cardiac diseases. A revolutionary approach would be to use smart materials to support or restore cardiac mechanical function. The interdisciplinary team involved will develop prototypes of implantable autonomous devices made with smart materials and interplaying with cardiac rhythm monitor/control systems *in situ*. This paves the way for new biomedical technologies that will lead to enhanced quality of life and survival rates for one of the largest patient groups worldwide.

CELLINK has been awarded Horizon 2020 - Emerging paradigms and communities funding from the EU for the project "REPAIR: Restoring Cardiac Mechanical Function by Polymeric Artificial Muscular Tissue." CELLINK and its 8 partners (Università degli studi di Firenze, Scuola Superiore di Studi Universitari e di Perfezionamento Sant'Anna, Universiteit Maastricht, Szegedi Tudományegyetem, Delft University of Technology, Consiglio Nazionale delle Ricerche, Centre Hospitalier Universitaire Vaudois, MEDTRONIC Bakken Research Center B.V., and SPECIFIC POLYMERS) have received funding for the project at 100 percent of its total estimated costs, approximately €3,910,000. The REPAIR project will be coordinated by Prof. Corrado Poggesi of Università degli studi di Firenze. The project spans over 48 months and CELLINK's share of the project corresponds to €270,000. The company does not incur any costs for the project. CELLINK's counter-performance is entirely within the lines of the company's regular operations.

This project has received funding from the European Union's Horizon 2020 FET-Proactive programme under grant No. 952166 REPAIR.

For further information, please contact:

**Erik Gatenholm, CEO**  
Phone (Sweden): +46 73 267 00 00  
Phone (US): +1 (650) 515 5566  
Email: [eg@cellink.com](mailto:eg@cellink.com)

**Gusten Danielsson, CFO**  
Phone (Sweden): +46 70 991 86 04  
Phone (US): +1 (857) 332 2138  
Email: [gd@cellink.com](mailto:gd@cellink.com)

## About CELLINK

Founded in 2016, CELLINK is a global life-science company that provides technologies, products and services to create, understand, and master cell and molecular biology. With a focus on the application areas of bioprinting, analysis, and liquid handling and bioprocessing, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK's products are trusted by more than 1,000 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 55 countries, and have been cited in more than 150 publications. CELLINK is creating the future of medicine.

Visit [cellink.com](http://cellink.com) to learn more. CELLINK is listed on the Nasdaq Stockholm Main Market under CLNK B.